GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VioQuest Pharmaceuticals Inc (OTCPK:VOQP) » Definitions » EPS without NRI

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) EPS without NRI : $-2.31 (TTM As of Jun. 2008)


View and export this data going back to . Start your Free Trial

What is VioQuest Pharmaceuticals EPS without NRI?

VioQuest Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Jun. 2008 was $-0.38. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2008 was $-2.31.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for VioQuest Pharmaceuticals's EPS without NRI or its related term are showing as below:

VOQP's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.05
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

VioQuest Pharmaceuticals's EPS (Diluted) for the three months ended in Jun. 2008 was $-0.38. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2008 was $-2.21.

VioQuest Pharmaceuticals's EPS (Basic) for the three months ended in Jun. 2008 was $-0.38. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2008 was $-2.21.


VioQuest Pharmaceuticals EPS without NRI Historical Data

The historical data trend for VioQuest Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VioQuest Pharmaceuticals EPS without NRI Chart

VioQuest Pharmaceuticals Annual Data
Trend Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.60 -2.40 -4.70 -1.30 -2.10

VioQuest Pharmaceuticals Quarterly Data
Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.70 -0.60 -0.63 -0.38

Competitive Comparison of VioQuest Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, VioQuest Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VioQuest Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VioQuest Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where VioQuest Pharmaceuticals's PE Ratio without NRI falls into.



VioQuest Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VioQuest Pharmaceuticals  (OTCPK:VOQP) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


VioQuest Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of VioQuest Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 2287, Minneapolis, MN, USA, 55402
Website
VioQuest Pharmaceuticals Inc is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment.
Executives
Mark D Dacko director, officer: CFO and Secretary 800 NICOLLET MALL SUITE 2690, MINNEAPOLIS MN 55402
Christopher P. Schnittker officer: V.P. & Chief Financial Officer 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Brian Lenz officer: CFO and Treasurer 65 COMMERCE WAY, HACKENSACK NJ 07601
Lau Johnson Yiu Nam director
Michael Weiser director C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Stephen Rocamboli director, officer: Secretary C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Daniel E Greenleaf director, officer: President and CEO C/O NABI BIO PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Lester E Lipschutz 10 percent owner WOLF BLOCK SCHORR AND SOLIS COHEN, 1650 ARCH STREET, PHILADELPHIA PA 19103
David M Tanen director TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Headlines

No Headlines